REVIVA PHARMACEUTICALS HOLDI (RVPH) Fundamental Analysis & Valuation
NASDAQ:RVPH • US76152G1004
Current stock price
2.32 USD
-0.25 (-9.73%)
At close:
2.3685 USD
+0.05 (+2.09%)
After Hours:
This RVPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RVPH Profitability Analysis
1.1 Basic Checks
- In the past year RVPH has reported negative net income.
- RVPH had a negative operating cash flow in the past year.
- RVPH had negative earnings in 4 of the past 5 years.
- RVPH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- RVPH has a Return On Assets of -158.77%. This is amonst the worse of the industry: RVPH underperforms 84.38% of its industry peers.
- Looking at the Return On Equity, with a value of -500.18%, RVPH is doing worse than 80.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -158.77% | ||
| ROE | -500.18% | ||
| ROIC | N/A |
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RVPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. RVPH Health Analysis
2.1 Basic Checks
- The number of shares outstanding for RVPH has been increased compared to 1 year ago.
- Compared to 5 years ago, RVPH has more shares outstanding
- The debt/assets ratio for RVPH is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -4.20, we must say that RVPH is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -4.20, RVPH perfoms like the industry average, outperforming 40.10% of the companies in the same industry.
- There is no outstanding debt for RVPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.2 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.39 indicates that RVPH should not have too much problems paying its short term obligations.
- RVPH has a Current ratio of 1.39. This is in the lower half of the industry: RVPH underperforms 72.92% of its industry peers.
- RVPH has a Quick Ratio of 1.39. This is a normal value and indicates that RVPH is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.39, RVPH is doing worse than 65.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.39 |
3. RVPH Growth Analysis
3.1 Past
- The earnings per share for RVPH have decreased strongly by -249.55% in the last year.
EPS 1Y (TTM)-249.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-380%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, RVPH will show a very strong growth in Earnings Per Share. The EPS will grow by 21.62% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.3%
EPS Next 2Y32.56%
EPS Next 3Y18.76%
EPS Next 5Y21.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. RVPH Valuation Analysis
4.1 Price/Earnings Ratio
- RVPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RVPH's earnings are expected to grow with 18.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.56%
EPS Next 3Y18.76%
5. RVPH Dividend Analysis
5.1 Amount
- No dividends for RVPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RVPH Fundamentals: All Metrics, Ratios and Statistics
2.32
-0.25 (-9.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners9.74%
Inst Owner Change-98.31%
Ins Owners3.01%
Ins Owner Change0%
Market Cap271.09M
Revenue(TTM)N/A
Net Income(TTM)-22.76M
Analysts81.67
Price TargetN/A
Short Float %N/A
Short Ratio6.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.25%
Min EPS beat(2)-6.95%
Max EPS beat(2)39.44%
EPS beat(4)3
Avg EPS beat(4)23.56%
Min EPS beat(4)-6.95%
Max EPS beat(4)39.44%
EPS beat(8)7
Avg EPS beat(8)18.04%
EPS beat(12)8
Avg EPS beat(12)-2.4%
EPS beat(16)11
Avg EPS beat(16)0.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.69%
PT rev (3m)-6.83%
EPS NQ rev (1m)-1900%
EPS NQ rev (3m)-1481.92%
EPS NY rev (1m)5.42%
EPS NY rev (3m)7.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 59.58 | ||
| P/tB | 59.58 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.88
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -158.77% | ||
| ROE | -500.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.39 | ||
| Altman-Z | -4.2 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-249.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-380%
EPS Next Y58.3%
EPS Next 2Y32.56%
EPS Next 3Y18.76%
EPS Next 5Y21.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.57%
OCF growth 3YN/A
OCF growth 5YN/A
REVIVA PHARMACEUTICALS HOLDI / RVPH Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for REVIVA PHARMACEUTICALS HOLDI?
ChartMill assigns a fundamental rating of 1 / 10 to RVPH.
What is the valuation status of REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?
ChartMill assigns a valuation rating of 0 / 10 to REVIVA PHARMACEUTICALS HOLDI (RVPH). This can be considered as Overvalued.
What is the profitability of RVPH stock?
REVIVA PHARMACEUTICALS HOLDI (RVPH) has a profitability rating of 0 / 10.